Jefferies Global Healthcare Conference
Logotype for H. Lundbeck

H. Lundbeck (LUN) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for H. Lundbeck

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Strategic reset and growth

  • Three-year reset focused on growing existing assets, building a long-term pipeline and disciplined capital allocation; the next phase is a scale phase.

  • Growth outlook extended to more than 2x the original 2023–2026 plan, based on October 2024 mid-term guidance and CER growth.

  • The ambition to build five to six mid- and late-stage assets was delivered; the pipeline shifted from lifecycle management and early-stage assets to a differentiated, more sustainable portfolio.

  • Commercial changes, partnership modifications, manufacturing optimization and fast deleveraging freed capital for growth and pipeline investment.

Commercial growth

  • Vyepti grew 45% CER and was described as the fastest-growing anti-CGRP in the U.S.; earlier-line use, Asia launches and European investment are growth opportunities, with IV administration not viewed as a limitation.

  • Rexulti grew 13% CER, with resilient momentum across indications; U.S. Alzheimer’s disease agitation was a key growth engine alongside MDD, and patients aged 65+ represent 37% of prescriptions.

  • MDD prescription growth was nearly 14% and AADAD growth was 29%; IRA pricing impact is expected in 2028, with further mid-term guidance planned for Q1 2027.

  • Vyepti and Rexulti have doubled the growth rate targeted three years ago, supporting a more durable growth engine.

Pipeline and catalysts

  • Bexicaserin DEEp OCEAN pivotal results are expected by end-2026 and DEEp SEA results in Q1 2027; broader DEE treatment could target peak sales of DKK 1.5bn–2bn, while another estimate is USD 1.5–2bn.

  • Amlenetug’s phase III multiple system atrophy study completed randomization; readout is expected in Q3 2027 from a 400-patient study building on phase II proof of concept.

  • Bocunebart phase III in chronic migraine was planned to start in 2026; anti-PACAP asedebart showed a 5.9-day LS mean reduction in monthly migraine days, while bocunebart showed cortisol normalization proof of concept in Cushing’s disease.

  • Phase Ib D1/D2 agonist Lu AF289964 showed 3.6 hours of good ON-time gained and 2.3 hours of OFF-time reduced at week 6 in advanced Parkinson’s disease; the pipeline also includes 16 special regulatory designations and a promising earlier-stage orexin program.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from H. Lundbeck